Foresight diagnostics trial#

Foresight diagnostics trial#

The open label trial is evaluating patients with newly diagnosed aggressive B-cell lymphoma and is designed such that patients first received the BTK inhibitor acalabrutinib for up to 14 days. In routine clinical care, using a tool like PhasED-Seq to study treatment response in real-time could enable physicians to direct management decisions earlier in the treatment process.” “Despite significant advances in how we treat patients with B-cell lymphomas, we still monitor disease burden and response to therapy primarily through CT imaging,” said Mark Roschewski, M.D., Lymphoid Malignancies Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD., and principal investigator of the study “This study found that changes in MRD levels may predict response to acalabrutinib treatment in as few as seven days and also suggested that ctDNA quantification by PhasED-Seq may demonstrate clinical response prior to CT scans in some cases. The study ( abstract #524) was described in a podium presentation at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Detection of ctDNA levels with PhasED-Seq was highly correlated with CT imaging and rapidly detected changes in tumor burden in newly diagnosed aggressive B-cell lymphoma patients treated with the drug. 13, 2021 (GLOBE NEWSWIRE) - Foresight Diagnostics, in collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, today announced results from an ongoing phase 2 clinical trial of the lymphoma drug acalabrutinib that included Foresight’s proprietary circulating tumor DNA (ctDNA) detection and minimum residual disease (MRD) monitoring assay, Phased variant Enrichment and Detection Sequencing (PhasED-Seq). Podium presentation at the American Society of Hematology Annual Meeting & ExpositionĪURORA, Colo., Dec.

One patient with improved symptoms showed 20-fold drop in ctDNA despite no changes on CT imaging, suggesting that ctDNA changes may precede CT changes in some cases.

PhasED-Seq ctDNA detection may predict response to targeted agents as early as seven days.PhasED-Seq ctDNA detection results were highly correlated with CT imaging.